If by today's hit by Adam Feuerstein perhaps we should start to feel bad for the man? with no shame continually picking on a biotech with soon to have 4 mid-phase (Phase 2, x4) trials and now the deepest dig he can find is "their drug Kevetrin is the least likely to succeed." Thanks, Adam, so, you've given the Cellceutix pipeline an endorsement for success! Perhaps his next Cellceutix hit he will accidentally write, "Help me short Cellceutix, I'm having an increasingly hard time at it!"
Back to the science.
2017 will yield 3 or 4 topline results for Phase 2 drugs that have shown tremendous promise in the lead-up. And reference the last PR in Brilacidin. Go back and read it...
I remain as enthusiastic and confident that Cellceutix will enter into a major (not JV) partnership or be acquired within the next 10-14 months.
For people with BS detectors, the recent Mako and Adam Feuerstein hits should set their bells ringing and also alert them that the deeper you go in FDA trials and the closer you keep signal to partnerships, the more and more the Nats are going to keep swarming you.
So, get used to it folks. The deeper we go, the more we signal that we have drugs that are kicking arse, the more swarms will attack.
I'm sticking to my theory that sometime in March or April--CTIX is sitting at $2-3 on whichever interim results they release first...second leg of my theory, shows a major move up on topline data followed by a fast partnership sometime in summer.
Good luck CTIX flock! Perseverance will be rewarded for the wise.
News 
Market Data 
Discover 
AI
